Value of albumin-bilirubin score combined with aspartate aminotransferase-to-platelet ratio index in predicting the development of posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma

Mai RongYun; Ye JiaZhou; Wang YanYan; Bai Tao; Chen Jie; Huang Shan; Wu GuoBin; Wu FeiXiang; Zhao YinNong; Li LeQun

doi:10.3969/j.issn.1001-5256.2018.02.015

Issue 2

Feb. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(2): 292-297

PDF( 1845 KB)

Value of albumin-bilirubin score combined with aspartate aminotransferase-to-platelet ratio index in predicting the development of posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2018.02.015

Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University

Research funding:

Published Date: 2018-02-20

Abstract

Abstract

Objective To investigate the value of albumin-bilirubin (ALBI) score combined with aspartate aminotransferase-to-platelet ratio index (APRI) in predicting the development of posthepatectomy liver failure (PHLF) in patients with HBV-related hepatocellular carcinoma (HCC) .Methods A retrospective analysis was performed for the patients with HBV-related HCC who underwent hepatectomy in The Affiliated Tumor Hospital of Guangxi Medical University from January 2006 to October 2013.With Child-Pugh score as control, the values of ALBI, APRI, and ALBI combined with APRI in predicting PHLF were analyzed.The chi-square test or the Fisher exact test was used for comparison of categorical data between groups, and the logistic regression model was used to identify independent predictive indices for PHLF.Results A total of 1055 patients were enrolled in this study, among whom 151 (14.3%) experienced PHLF.The univariate and multivariate analyses showed that ALBI and APRI were significantly associated with the prognosis of PHLF patients (P < 0.001) .ALBI and APRI had a significantly higher area under the receiver operating characteristic curve (AUC) than Child-Pugh score (both P<0.001) .albi="" had="" a="" sensitivity="" of="" and="" specificity="" in="" predicting="" phlf="" at="" the="" optimal="" cut-off="" value="" patients="" with="" albi="">-2.77 had a significantly higher incidence rate of PHLF A/B/C than those with ALBI ≤-2.77 (P < 0.001) .APRI had a sensitivity of 61.6% and a specificity of 71.0% in predicting PHLF at the optimal cut-off value of 0.85, and the patients with APRI >0.85 had a significantly higher incidence rate of PHLF A/B/C than those with APRI ≤0.85 (P < 0.001) .The combination of ALBI and APRI had a significantly higher AUC than ALBI or APRI (P < 0.001 and P = 0.047) .The combination of ALBI and APRI had a sensitivity of 78.1% and a specificity of 62.2% in predicting PHLF at the optimal cut-off value of-13.10, and the patients with the combination of ALBI and APRI >-13.10 had a significantly higher incidence rate of PHLF A/B/C than those with the combination of ALBI and APRI ≤-13.10 (P < 0.001) .Conclusion ALBI combined with APRI can be used as a new, convenient, and reliable index for predicting PHLF.
- carcinoma, hepatocellular,
- hepatectomy,
- liver failure,
- risk factors

FullText(HTML)

References(27)

References

[1]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.

[2]CHU KK, CHEUNG TT.Update in management of hepatocellular carcinoma in Eastern population[J].World J Hepatol, 2015, 7 (11) :1562-1571.

[3]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[4]EL-SERAG HB.Hepatocellular carcinoma[J].N Engl J Med, 2011, 365 (12) :1118-1127.

[5]LIN F.Research advances in clinical diagnosis, prognostic evaluation, and treatment of liver failure[J].J Clin Hepatol, 2016, 32 (9) :1678-1683. (in Chinese) 林锋.肝衰竭的临床诊断、预后评估和治疗进展[J].临床肝胆病杂志, 2016, 32 (9) :1678-1683.

[6]Mc CORMACK L, PETROWSKY H, JOCHUM W, et al.Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy:a matched case-control study[J].Ann Surg, 2007, 245 (6) :923-930.

[7]DURAND F, VALLA D.Assessment of the prognosis of cirrhosis:Child-Pugh versus MELD[J].J Hepatol, 2005, 42 (Suppl 1) :s100-s107.

[8]JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al.Assessment of liver function in patients with hepatocellular carcinoma:a new evidence-based approach-the ALBI grade[J].J Clin Oncol, 2015, 33 (6) :550-558.

[9]WANG YY, ZHONG JH, SU ZY, et al.Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J].Br J Surg, 2016, 103 (6) :725-734.

[10]WAI CT, GREENSON JK, FONTANA RJ, et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J].Hepatology, 2003, 38 (2) :518-526.

[11]CASTERA L, VERGNIOL J, FOUCHER J, et al.Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C[J].Gastroenterology, 2005, 128 (2) :343-350.

[12]ICHIKAWA T, UENISHI T, TAKEMURA S, et al.A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma[J].J Hepatobiliary Pancreat Surg, 2009, 16 (1) :42-48.

[13]BERZIGOTTI A, REIG M, ABRALDES JG, et al.Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis:a systematic review and meta-analysis[J].Hepatology, 2015, 61 (2) :526-536.

[14]RAHBARI NN, GARDEN OJ, PADBURY R, et al.Posthepatectomy liver failure:a definition and grading by the International Study Group of Liver Surgery (ISGLS) [J].Surgery, 2011, 149 (5) :713-724.

[15]DINDO D, DEMARTINES N, CLAVIEN PA.Classification of surgical complications:a new proposal with evaluation in a cohort of6336 patients and results of a survey[J].Ann Surg, 2004, 240 (2) :205-213.

[16]PUTTER H, FIOCCO M, GESKUS RB.Tutorial in biostatistics:competing risks and multi-state models[J].Stat Med, 2007, 26 (11) :2389-2430.

[17]LI FW, LEI ZQ, ZHANG QQ, et al.Establishment of nomogram model for predicting posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma[J/CD].Chin J Hepatic Surg:Electronic Edition, 2017, 6 (5) :358-362. (in Chinese) 李风伟, 雷正清, 张茜茜, 等.预测HBV相关肝细胞癌肝切除术后肝衰竭列线图模型的建立[J/CD].中华肝脏外科手术学电子杂志, 2017, 6 (5) :358-362.

[18]WIESNER R, EDWARDS E, FREEMAN R, et al.Model for end-stage liver disease (MELD) and allocation of donor livers[J].Gastroenterology, 2003, 124 (1) :91-96.

[19]CHEN RC, CAI YJ, WU JM, et al.Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis[J].J Viral Hepat, 2017, 24 (3) :238-245.

[20]KUO YH, WANG JH, HUNG CH, et al.The ALBI grade predicts the prognosis of patients with advanced hepatocellular carcinoma received sorafenib[J].J Gastroenterol Hepatol, 2017.[Epub ahead of print]

[21]HIRAOKA A, KUMADA T, MICHITAKA K, et al.Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2016, 31 (5) :1031-1036.

[22]DIENSTAG JL.The role of liver biopsy in chronic hepatitis C[J].Hepatology, 2002, 36 (5 Suppl 1) :s152-s160.

[23]LOAEZA-DEL-CASTILLO A, PAZ-PINEDA F, OVIEDOCARDENAS E, et al.AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis[J].Ann Hepatol, 2008, 7 (4) :350-357.

[24]SOOKOIAN S, CASTANO GO, SCIAN R, et al.Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level[J].Am J Clin Nutr, 2016, 103 (2) :422-434.

[25]OKUDA M, LI K, BEARD MR, et al.Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein[J].Gastroenterology, 2002, 122 (2) :366-375.

[26]SHEN SL, FU SJ, CHEN B, et al.Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection[J].Ann Surg Oncol, 2014, 21 (12) :3802-3809.

[27]CHENG J, ZHAO P, LIU J, et al.Preoperative aspartate aminotransferase-to-platelet ratio index (APRI) is a predictor on postoperative outcomes of hepatocellular carcinoma[J].Medicine (Baltimore) , 2016, 95 (48) :e5486.

Relative Articles

[1]	Aiping TIAN, Yongfeng YANG. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 491-497. doi: 10.3969/j.issn.1001-5256.2023.03.002
[2]	Liang XU, Ping LI, Lin CHEN, Yuqiang FU. Natural history and non-invasive diagnosis and clinical management of chronic HBV infection overlapping with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1501-1507. doi: 10.3969/j.issn.1001-5256.2021.07.003
[3]	Aiping WANG, Chunyang WEN. Thoughts on recommendations for immune-tolerant phase of chronic hepatitisB virus infection in Guidelines for the management of hepatitis B (version 3.3) released by the Japan Society of Hepatology[J]. Journal of Clinical Hepatology, 2021, 37(7): 1528-1528. doi: 10.3969/j.issn.1001-5256.2021.07.009
[4]	Li XIAO, Jianchun XIAN. Patients in the immune-tolerant phase of chronic hepatitis B can receive antiviral therapy conditionally[J]. Journal of Clinical Hepatology, 2021, 37(4): 781-782. doi: 10.3969/j.issn.1001-5256.2021.04.010
[5]	Jun JIANG, Fuzhong WU, Deyang WANG. Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent[J]. Journal of Clinical Hepatology, 2021, 37(11): 2545-2545. doi: 10.3969/j.issn.1001-5256.2021.11.010
[6]	Ling QING, Weiqiang HUANG, Xiaohe LI, Feng CHEN, Yingxia LIU. Efficacy of antiviral therapy for chronic hepatitis B with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2075-2080. doi: 10.3969/j.issn.1001-5256.2021.09.015
[7]	Yang DING, Xiaoguang DOU. How far are we from the "Treat all" era of antiviral therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(11): 2546-2547. doi: 10.3969/j.issn.1001-5256.2021.11.011
[8]	Lina JIANG, Wei Li, Jingmin ZHAO. Current status and perspectives of the clinical and basic research on concomitant chronic hepatitis B virus infection and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1489-1494. doi: 10.3969/j.issn.1001-5256.2021.07.001
[9]	Yanhua TANG, Xingyu LU, Jian SUN. Chronic hepatitis B virus infection with nonalcoholic fatty liver disease: Problems faced by antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(7): 1508-1514. doi: 10.3969/j.issn.1001-5256.2021.07.004
[10]	Li WenMi, Wang Nan, Bian Qian, Huang Qian, Li JingTao, Wei HaiLiang, Yan ShuGuang. Role of liver X receptor in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2349-2352. doi: 10.3969/j.issn.1001-5256.2020.10.041
[11]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[12]	Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
[13]	Lu BingJie, Chen Xi, Sun MingYu. Application of lipid-regulating drugs in prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2444-2448. doi: 10.3969/j.issn.1001-5256.2017.12.043
[14]	Xie Xiao, Lu LunGen. Potential therapeies for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2439-2443. doi: 10.3969/j.issn.1001-5256.2017.12.042
[15]	Feng Gong, Niu ChunYan. Advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2433-2438. doi: 10.3969/j.issn.1001-5256.2017.12.041
[16]	Guo YinYan, Li Peng. A study on the role of serum Retinol Binding Protein 4 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(4): 279-280+301.
[17]	Qiu RongYuan, He ShengSong, Chen Feng, Pang Ran. Construction of eukaryotic expression vector of P21 mutation type by nuclear location signal and its effect on virus replication in HepG2.2.15 Cells[J]. Journal of Clinical Hepatology, 2010, 26(4): 387-391.
[18]	Chen Sheng, Lin ChaoShuang. The relationship between liver function and immune system and viral replication in patients with viral hepatitis[J]. Journal of Clinical Hepatology, 2007, 23(2): 94-95.
[19]	Yang XiaoJuan, Wu GuoRong, Lu ZhongHua, Pei Hao, Qian JinJuan. Clinical signification of detecting PreS;antigen for identifying viral replication in patients with HB without HbeAg[J]. Journal of Clinical Hepatology, 2007, 23(5): 340-341.

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	张明. 酒精性肝病合并乙型肝炎病毒感染病例临床分析. 中国医药指南. 2024(02): 114-116 .
2.	吴琦玮，高杨，李艳辉，沈榕. 2015—2019年北京地区乙型肝炎疾病负担及趋势预测分析. 实用预防医学. 2024(11): 1349-1352 .
3.	董丹丹，邱利，胡毅. 慢性HBV感染合并非酒精性脂肪性肝病患者血清脂联素、ROS及糖脂代谢特征. 肝脏. 2024(10): 1265-1268+1273 .
4.	毛垚耀，何惠昌，谢露，崔健娇，刘光伟. 健脾活血解毒方联合恩替卡韦对乙型病毒性肝炎合并非酒精性脂肪性肝病小鼠的干预作用及机制. 现代中西医结合杂志. 2023(08): 1047-1052 .
5.	沈从乐，李韦杰，任博，孙继云，王雅杰. 2543例不同病因慢性肝病糖脂代谢异常率分析. 标记免疫分析与临床. 2022(09): 1451-1454 .
6.	倪盟，曾雷. miRNA单核苷酸多态性与HBV感染相关疾病关系的研究进展. 吉林大学学报(医学版). 2021(06): 1588-1593 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2655) PDF downloads(573)

Value of albumin-bilirubin score combined with aspartate aminotransferase-to-platelet ratio index in predicting the development of posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2018.02.015